RxDoctor Payments Data

Michael Lumberg, MD

Internal Medicine · Troy, MINPI 1700853447

Payments from drug & device makers

$3,532in general payments, 2019–2025

Across 92 payments — averaging $38.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$774
  • Novo Nordisk$704
  • AstraZeneca$377
  • Pfizer$345
  • AbbVie$309
  • GSK$278
  • plus $745 from 11 others

What the payments were for

  • Food & beverage$3,527100%
  • Education$50%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,532 in reported general payments places this provider in the 85th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$246,474
Medicare patients
359
Services billed
6,233

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin168$258,589
OzempicSemaglutide87$122,260
EliquisApixaban80$98,976
TrulicityDulaglutide39$73,338
MounjaroTirzepatide59$66,130
FarxigaDapagliflozin Propanediol30$44,801
XareltoRivaroxaban20$31,710
Repatha SureclickEvolocumab18$23,460
JanuviaSitagliptin Phosphate17$22,389
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$16,839
Rosuvastatin Calcium608$11,769
Breo ElliptaFluticasone/Vilanterol17$9,536
Atorvastatin Calcium652$8,265
Olmesartan Medoxomil237$7,631
Tresiba Flextouch U-100Insulin Degludec12$6,872

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$139$258,589168 claims
Lilly USA, LLCTrulicity, Mounjaro$90$139,46898 claims
Novo NordiskOzempic$704$122,26087 claims
PfizerEliquis$345$98,97680 claims
AstraZenecaFarxiga$377$44,80130 claims
Johnson & JohnsonXarelto$144$31,71020 claims
MerckJanuvia$95$22,38917 claims
GSKBreo Ellipta, Shingrix$278$13,96837 claims
AbbVieSynthroid$309$3,58638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Troy

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →